Autologous cytomegalovirus-specific T cell as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia

12Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

B-cell chronic lymphocytic leukaemia (B-CLL) cells express low levels of co-stimulatory molecules and therefore fail to induce activation and differentiation of tumour-specific T cells. We have shown that patients with B-CLL have considerably expanded numbers of cytomegalovirus (CMV) reactive CD8+ T cells. This study demonstrated that B-CLL cells loaded with CMV peptide not only promoted the ex vivo expansion of autologous, in vivo-generated virus-specific T cells, but also constituted excellent target cells for these cytotoxic T cells, even without ex vivo re-stimulation. Directing virus-specific T cells to B-CLL may overcome the inadequate immunostimulatory capacity of these cells, which could be exploited for T-cell mediated immunotherapy.

Cite

CITATION STYLE

APA

Kater, A. P., Remmerswaal, E. B. M., Nolte, M. A., Eldering, E., Van Oers, M. H. J., & Van Lier, R. A. W. (2004). Autologous cytomegalovirus-specific T cell as effector cells in immunotherapy of B cell chronic lymphocytic leukaemia. British Journal of Haematology, 126(4), 512–516. https://doi.org/10.1111/j.1365-2141.2004.05070.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free